Influenza A H1N1 antibody

100% Secure

Goat anti Influenza A H1N1:HRP

Goat anti Influenza A H1N1

Product Type
Polyclonal Antibody
Isotype
Polyclonal IgG
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
5315-0304 P 1 ml
5315-0064 H IF P 1 ml
Goat anti Influenza A H1N1 polyclonal antibody is specific for Influenza A virus H1N1 by Haemagglutination inhibition.

This goat anti Influenza A H1N1 polyclonal antibody does not react with Influenza B, RSV, Para 1-3 or Adenovirus. It does not react with HEp-2 cells but may react with some chicken cellular proteins.

Influenza type A viruses are divided into subtypes based on the antigenic differences of two viral surface proteins, hemagglutinin (H) and neuraminidase (N). On infection of the respiratory tract, the hemagglutinin molecule binds to sialic acid-containing receptors on the epithelial cells resulting in endocytosis. Once the virus has been engulfed, the hemagglutinin allows the viral membrane to fuse with the endosomal membrane. Neuraminidase functions to aid viral release from host cells by cleaving terminal sialic acid residues from carbohydrate moieties on the cell surface. Viral release also requires the interaction of the viral M1 protein with the celular scaffold G-like protein RACK1 (Demirov et al. 2012).

Subtype antigenic variations result from a process known as antigenic drift whereby these surface proteins constantly mutate in order to evade the host immune repspone. Subtype A(H1N1) was the cause of Spanish flu pandemic that killed approximately 50,000,000 people between 1918-1919.

Product Details

Target Species
Viral
Product Form
Purified IgG - liquid
Product Form
Purified IgG - liquid
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.002%Thiomersal
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide (NaN3)
Immunogen
Influenza A, strain USSR (H1N1)
Approx. Protein Concentrations
1.0 mg/ml
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml

Storage Information

Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.

More Information

Regulatory
For research purposes only

Applications of Influenza A H1N1 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Immunohistology - Paraffin 1/20 1/200
Haemagglutination
Immunofluorescence
Immunohistology - Paraffin
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Rabbit anti Goat IgG (Fc):FITC STAR122F 1 mg F
Rabbit anti Goat IgG (Fc):HRP STAR122P 1 mg C E WB

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
AbGUARD® HRP Stabilizer Plus BUF052A 100 ml C E P WB
AbGUARD® HRP Stabilizer Plus BUF052B 500 ml C E P WB
AbGUARD® HRP Stabilizer Plus BUF052C 1000 ml C E P WB
Antigen Retrieval Buffer, pH8.0 BUF025A 500 ml P
Antigen Retrieval Buffer, pH8.0 BUF025C 50 ml P

Application Based External Images

Immunofluorescence

Immunohistology - Paraffin

Product Specific References

References for Influenza A H1N1 antibody

  1. Demirov, D. et al. (2012) Interaction of influenza A virus matrix protein with RACK1 is required for virus release.
    Cell Microbiol. 14: 774-89.
  2. Zielecki, F. et al. (2010) Virulence determinants of avian H5N1 influenza A virus in mammalian and avian hosts: The role of the C-terminal ESEV motif in the viral NS1 protein.
    J Virol. 117: 439 - 48
  3. Kash JC et al. (2011) Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses.
    MBio. 2(5). pii: e00172-11.
  4. Meunier, I. and von Messling, V. (2012) PB1-F2 Modulates Early Host Responses but Does not Affect the Pathogenesis of H1N1 Seasonal Influenza Virus.
    J Virol. 86: 4271-8.
  5. Nicol, M.Q. et al. (2012) A novel family of peptides with potent activity against influenza A viruses.
    J Gen Virol. 93: 980-6.
  6. Weinheimer, V.K. et al. (2012) Influenza A viruses target type II pneumocytes in the human lung.
    J Infect Dis. 206: 1685-94.
  7. Weinheimer, V.K. et al. (2012) Influenza A viruses target type II pneumocytes in the human lung.
    J Infect Dis. 206 (11): 1685-94.
  8. Kallfass, C. et al. (2013) Visualizing the beta interferon response in mice during infection with influenza A viruses expressing or lacking nonstructural protein 1.
    J Virol. 87 (12): 6925-30.
  9. Schliehe, C. et al. (2015) The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection.
    Nat Immunol. 16 (1): 67-74.